Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaoer Dingchuan Oral Liquid is a Traditional Chinese Medicine (TCM) formulation specifically developed for pediatric use to treat bronchial asthma and acute asthma exacerbations. It is primarily indicated for patients presenting with "heat syndrome," which includes symptoms such as cough, wheezing, and fever. The formulation typically consists of a standardized blend of herbal extracts, including Ephedra, Scutellaria, and Ginkgo, which work synergistically to clear lung heat, resolve phlegm, and stabilize wheezing. In clinical practice, it is often utilized as an adjunctive therapy alongside conventional treatments like inhaled corticosteroids and bronchodilators to improve symptom control and lung function in children.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xiaoer dingchuan oral liquid.